Hypogonadism Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Hypogonadism Treatment market is segmented By Type (Primary Hypogonadism ​, Central Hypogonadism), By Treatment Type (Testosterone Replacement Therapy, Estrogen Therapy, Progesterone Therapy), By Route of Administration, and Geography.

Hypogonadism Treatment Market Snapshot

hypogonadism treatment market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3 %
hypogonadism treatment market size

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Hypogonadism Treatment Market is expected to register a CAGR of 3% during the forecast period attributing to increase in the incidence of hypogonadism, a rise in awareness about the disease and its treatment options and growth of infertility rate. Moreover, high risk of hypogonadism in the geriatric population and patient pool with diabetes and obesity are also some of the key drivers in the hypogonadism treatment market. For instance, according to a report published by the National Institute of Health (NIH), in 2019 obesity is increasing worldwide and the prevalence of hypogonadism is significantly greater in males with obesity. In addition, men aged between 60-80 years have low testosterone levels by 20% and 80% than normal testosterone levels in young men. Men above 60 years have the highest prevalence of hypogonadism. Thus, countries surging the geriatric population are witnessing a high demand for therapies to treat hypogonadism, hence, driving the hypogonadism market.

Scope of the Report

Hypogonadism is a rare hormonal disorder characterized by insufficient production of testes or ovaries, result in diminished production of sex hormones. Hypogonadism Treatment Market is segmented By Type, Treatment Type, Route of Administration and Geography.

By Type
Primary Hypogonadism
Central Hypogonadism
By Treatment Type
Testosterone Replacement Therapy
Estrogen Therapy
Progesterone Therapy
By Route of Administration
Topical Gel
Transdermal Patch
Implantable Pellet
Oral Tablets
Others
By End User
Hospitals
Speciality Clinics
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

In Treatment Type Segment, Testosterone Replacement Therapy is Expected to Witness a Healthy Growth in Future

Testosterone replacement therapy is expected to contribute the largest revenue considering the fact that hypogonadism is more prevalent in men. Several government initiatives and product approvals are also boosting the testosterone replacement therapy. For instance, Clarus Therapeutics, in May 2019, received the FDA approval for Jatenzo testosterone, an oral testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. In addition, Antares Pharma received the FDA approval in 2018 for Xyosted (testosterone enanthate) Injection.

In addition, the decreasing rate of fertility is leading to the high chances of hypogonadism and promoting the revenue growth of the overall market

hypogonadism treatment market share

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the global hypogonadism treatment market throughout the forecast period. This dominance is mainly owing to increasing cases of hypogonadism with raising awareness about the hormonal disorder, increased adoption of newer highly advanced products and advanced healthcare infrastructure. As per the report published in the European Association of Urology Journal in the year 2017, testosterone prescription trends in the United States witnessed an increase between 1.8 and 4-fold over the last two decades (1997 - 2017) which is resulting in the growth of hypogonadism market.

 hypogonadism treatment market analysis

Competitive Landscape

The market studied is moderately competitive and there are several international companies present in this market. Some of the companies in the market are Abbott Laboratories Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Endo International, Ferring Pharmaceuticals, AbbVie Inc. and Merck Serono.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Risk of Hypogonadism in Geriatric Population

      2. 4.2.2 Lifestyle Issues

    3. 4.3 Market Restraints

      1. 4.3.1 Social Taboo

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type

      1. 5.1.1 Primary Hypogonadism

      2. 5.1.2 Central Hypogonadism

    2. 5.2 By Treatment Type

      1. 5.2.1 Testosterone Replacement Therapy

      2. 5.2.2 Estrogen Therapy

      3. 5.2.3 Progesterone Therapy

    3. 5.3 By Route of Administration

      1. 5.3.1 Topical Gel

      2. 5.3.2 Transdermal Patch

      3. 5.3.3 Implantable Pellet

      4. 5.3.4 Oral Tablets

      5. 5.3.5 Others

    4. 5.4 By End User

      1. 5.4.1 Hospitals

      2. 5.4.2 Speciality Clinics

      3. 5.4.3 Others

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle-East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle-East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories Inc

      2. 6.1.2 Eli Lilly and Company

      3. 6.1.3 Teva Pharmaceutical Industries Ltd

      4. 6.1.4 Endo International

      5. 6.1.5 Ferring Pharmaceuticals

      6. 6.1.6 AbbVie Inc.

      7. 6.1.7 Merck Serono

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Hypogonadism Treatment Market market is studied from 2018 - 2026.

The Hypogonadism Treatment Market is growing at a CAGR of 3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott Laboratories Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Endo International, Ferring Pharmaceuticals are the major companies operating in Hypogonadism Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!